AstraZeneca pays $1.2bn for lung treatment maker
Tuesday 11 June 2013
AstraZeneca has bought the US lung drug specialist Pearl Therapeutics for $1.15bn (£740m) as it continues to resuscitate its product pipeline through deals.
The drug maker is hoping to restore its fortunes after a string of late-stage research failures. It has also seen a number of big sellers fall out of patent, and its stalwarts Nexium and Crestor are set to lose their crucial US patent protection in 2014 and 2016 respectively.
The purchase of Pearl Therapeutics will give Astra a stronger foothold in the market for lung treatments by giving it access to a potential new treatment for chronic obstructive pulmonary disease, which is in late-stage development. The takeover is a signal that the company's chief executive, Pascal Soriot, pictured, believes its respiratory business is a core growth area.
Astra will pay an initial $560m, plus more if certain targets are met.
Mr Soriot said: "Chronic obstructive pulmonary disease continues to increase worldwide, and there is a growing need for the next generation of inhaled combination products.
"Pearl's novel formulation technology, together with its development products and specialist expertise are a great complement to AstraZeneca's long-established capabilities in respiratory disease, one of our core therapy areas."
The company has been in dealmaking mood for some time. Last month, it bought the heart specialist Omthera Pharmaceuticals for £293m. Omthera uses fish oils to produce treatments for people who are obese, diabetic or suffering from cardiovascular disease. Its big hope is Epanova, a pill aimed at lowering the level of triglyceride in blood.
Astra's shares rose 6.5p to 3,308p.
Separately the Irish drug maker Elan rejected another bid from Royalty Pharma yesterday, and said it was assessing inquiries from other interested parties.
Last week Royalty raised its bid to $8bn, the third increase in five months. Elan said the gap between what it believed to be the underlying value of the company and the new bid remained significant.
- 1 Autism 'caused by genetics', study suggests
- 2 What happens to your body when you give up sugar?
- 3 Why you should never make assumptions about people with autism
- 4 Tourist films plane's descent just metres above packed Caribbean beach
- 5 Have sex with your iPad thanks to the new sex toy no-one asked for
Tourist films plane's descent just metres above packed Caribbean beach
Bali nine: Welcome to 'Execution Island' – the Indonesian holiday resort where foreigners are sent to die
How Homer Simpson discovered the Higgs boson over a decade before scientists
The 'sex selfie stick' lets you FaceTime the inside of a vagina
Harrison Ford plane crash: Star Wars actor 'seriously injured' after light aircraft crash lands
Durham Free School: 'Creationism taught at' free school facing closure
Nearly 100,000 of Britain's poorest children go hungry after parents' benefits are cut
End of the licence fee: BBC to back radical overhaul of how it is funded
Ex-head of MI6: 'We shouldn't kid ourselves that Russia is on a path to democracy'
Most people think legal tax avoidance is just as wrong as illegal tax evasion, poll suggests
Nigel Farage promises Ukip will not 'stigmatise' would-be migrants – and says he wants 'everyone to speak the same language'
iJobs Money & Business
£13000 per annum: Recruitment Genius: This is an exciting opportunity to join ...
£25000 - £30000 per annum + benefits: Ashdown Group: A global leader operating...
£8 per hour: Recruitment Genius: This Pension Specialist was established early...
£30 - 35k + Bonus & Benefits: Guru Careers: We are seeking an Executive Assist...